NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells

CAR-transduced NK cell therapyПодробнее

Insights into NKG2D-targeting CAR-T cells in R/R AMLПодробнее

Engineering and Reprogramming Natural Killer Cells for Immunotherapy of CancerПодробнее

NKG2D CAR T-cells & soluble NKG2D ligandsПодробнее

Michael Jain, MD, regarding CAR-natural killer (NK) cell therapyПодробнее

CAR-T vs CAR-NK for myelomaПодробнее

Gene editing of NKG2A to enhance NK cell cytotoxicity against multiple myeloma cellsПодробнее

Las células NK primarias transducidas con NKG2D-CAR apuntan eficientemente a las células MMПодробнее

AlloCARs and CAR-NK cells in myelomaПодробнее

The current status of CAR T and CAR NK cells in multiple myelomaПодробнее

NKG2D CARs for R/R AML and MDSПодробнее

Rationale for NK-cell therapy in myelomaПодробнее

Natural Killer Cells: How Do They Kill Selectively?Подробнее

What are natural killer cells? #myelomaПодробнее

Meet the Unsung Immune Cell that Could Change Immunotherapy (Natural Killer Cells)Подробнее

Exploring Challenges With CAR T Cells and NK Cells in Multiple MyelomaПодробнее

Large Scale Genome Editing of Primary Human Natural Killer (NK) CellsПодробнее

Advanced cell therapy based on the chimeric receptor NKG2D: the NK-T cell approachПодробнее

FT596: iPSC-derived CAR-NK cells with engineered persistence for B-cell malignanciesПодробнее